ArticleCell death & disease2018
c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation.
Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Aloe-emodin inhibits nasopharyngeal carcinoma by modulating telomerase activity involving the c-Myc/E2F1 axis.Frontiers in pharmacology · 2026Article
- Unveiling vitamin C: A new hope in the treatment of diffuse large B‑cell lymphoma (Review).International journal of oncology · 2025Review
- Norchelerythrine fromInternational journal of oncology · 2025Article
- ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.Scientific reports · 2025Article
- Tetrandrine induces muscle atrophy involving ROS-mediated inhibition of Akt and FoxO3.Molecular medicine (Cambridge, Mass.) · 2024Article
- Tetrandrine targeting SIRT5 exerts anti-melanoma properties via inducing ROS, ER stress, and blocked autophagy.Journal of pharmaceutical analysis · 2024Article
- Article
- Combination of Ethacrynic Acid and ATRA Triggers Differentiation and/or Apoptosis of Acute Myeloid Leukemia Cells through ROS.Anti-cancer agents in medicinal chemistry · 2024Article
- Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential.Frontiers in oncology · 2022Review
- Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1Journal of immunology research · 2022Article
- Targeting the two-pore channel 2 in cancer progression and metastasis.Exploration of targeted anti-tumor therapy · 2022Review
- Progress on structural modification of Tetrandrine with wide range of pharmacological activities.Frontiers in pharmacology · 2022Review
- CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism.Frontiers in cell and developmental biology · 2021Article
- Saikosaponin D exhibits anti-leukemic activity by targeting FTO/mTheranostics · 2021Article
- Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Cell Death by Gallotannin Is Associated with Inhibition of the JAK/STAT Pathway in Human Colon Cancer Cells.Current therapeutic research, clinical and experimental · 2020Article
- Flavin Oxidase-Induced ROS Generation Modulates PKC Biphasic Effect of Resveratrol on Endothelial Cell Survival.Biomolecules · 2019Article
- Differentiation induction of human breast cancer cells by arsenite in combination with tetrandrine.American journal of translational research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tetrandrine is a broadly used bisbenzylisoquinoline alkaloid component of traditional Chinese medicine that has antitumor effects in some cancer types. In this study, we investigated the effects of tetrandrine on leukemia in vitro and in vivo. The results showed that tetrandrine effectively induced differentiation and autophagy in leukemia cells. In addition, tetrandrine treatment activated the accumulation of reactive oxygen species (ROS) and inhibited c-MYC protein expression. Further, we found that treatment with the ROS scavengers N-acetyl-L-cysteine (NAC) and Tiron as well as overexpression of c-MYC reduced tetrandrine-induced autophagy and differentiation. Moreover, a small molecular c-MYC inhibitor, 10058-F4, enhanced the tetrandrine-induced differentiation of leukemia cells. These results suggest that ROS generation and c-MYC suppression play important roles in tetrandrine-induced autophagy and differentiation, and the results from in vivo experiments were consistent with those from in vitro studies. Therefore, our data suggest that tetrandrine may be a promising agent for the treatment of leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.